Mandate

Advokatfirman Vinge has advised the sellers in connection with Tencent Holdings Ltd acquisition of Sharkmob AB

May 23, 2019 M&A

Advokatfirman Vinge has advised the sellers of the Swedish game developer Sharkmob in connection with Tencent Holdings acquisition of the company for an undisclosed sum.

​Sharkmob was founded two years ago by a tight-knit group of industry veterans, and they have since grown steadily at their iconic Malmö office. The studio will continue working with its unannounced online game as well as several new projects together with Tencent Holdings.

Tencent Holdings is a Hong Kong based tech company whose internet solutions are used by over one billion netizens (citizen of the net). Their two principal business operations are social platforms and digital content and they are widely recognized as the biggest gaming company in the world.

The full press release can be found here www.sharkmob.com/press-release.

“We engaged Advokatfirman Vinge and Christian Riddarbo in this transaction due to the firm´s extensive expertise in complex cross-border transactions and in particular working with and for Chinese companies which we understand often require experience of Chinese business structures, decision-making processes and specific legal considerations.”, said Kristofer Westergren, former shareholder and resigning Chairman of Sharkmob.

Vinge’s team primarily consisted of Christian Riddarbo (M&A), Fredrik Sonander (M&A), Victor Ericsson (Tax), Jenny Sandlund (M&A), Hampus Wahlberg (General Corporate), Adam Loewenstein (General Corporate) and Camilla Andersson (VDR).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026